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OBJECTIVE—Glucose-dependent insulinotropic polypeptide
(GIP), unlike glucagon-like peptide (GLP)-1, lacks glucose-low-
ering properties in patients with type 2 diabetes. We designed
this study to elucidate the underlying pathophysiology.
RESEARCH DESIGN AND METHODS—Twenty-two insulin-
naïve subjects with type 2 diabetes were given either synthetic
human GIP (20 ng  kg
1  min
1) or placebo (normal saline) over
180 min, starting with the ﬁrst bite of a mixed meal (plus1go f
acetaminophen) on two separate occasions. Frequent blood
samples were obtained over6ht odetermine plasma GIP, GLP-1,
glucose, insulin, glucagon, resistin, and acetaminophen levels.
RESULTS—Compared with placebo, GIP induced an early post-
prandial increase in insulin levels. Intriguingly, GIP also induced
an early postprandial augmentation in glucagon, a signiﬁcant
elevation in late postprandial glucose, and a decrease in late
postprandial GLP-1 levels. Resistin and acetaminophen levels
were comparable in both interventions. By immunocytochemis-
try, GIP receptors were present on human and mouse -cells. In
TC1 cell line, GIP induced an increase in intracellular cAMP and
glucagon secretion.
CONCLUSIONS—GIP, given to achieve supraphysiological
plasma levels, still had an early, short-lived insulinotropic
effect in type 2 diabetes. However, with a concomitant in-
crease in glucagon, the glucose-lowering effect was lost. GIP
infusion further worsened hyperglycemia postprandially, most
likely through its suppressive effect on GLP-1. These ﬁndings
make it unlikely that GIP or GIP receptor agonists will be
useful in treating the hyperglycemia of patients with type 2
diabetes. Diabetes 58:1342–1349, 2009
I
n response to glucose and fat in digested food,
two enteroendocrine hormones, glucagon-like
peptide (GLP)-1 and glucose-dependent insulino-
tropic polypeptide (GIP), are secreted from L- and
K-cells, respectively, in the gut. GLP-1 and GIP play impor-
tant roles in postprandial glucose homeostasis. In healthy
individuals, the potent insulinotropic effects of GLP-1 and
GIP account for up to 60% of the insulin secreted post-
prandially (1). Exogenous GLP-1 acts to improve glycemic
control in patients with type 2 diabetes by 1) stimulating
insulin secretion in a glucose concentration–dependent
manner during the fasted state, 2) suppressing glucagon
secretion in the presence of hyperglycemia and euglyce-
mia but not hypoglycemia, and 3) decelerating gastric
emptying, leading to a delay in the absorption of ingested
nutrients and a dampening of postprandial glucose excur-
sion (2–4). However, it is still unclear which of these
properties of exogenous GLP-1 plays a more prominent
role in lowering postprandial glucose (5). GIP has not been
studied as extensively as GLP-1. Similar to GLP-1, the
insulinotropic effect of GIP in healthy humans is glucose
concentration dependent under glucose clamp conditions
(6). Unlike GLP-1, the administration of GIP in healthy
humans was reported to have a dose-dependent glu-
cagonotropic effect during euglycemia and no effect during
hyperglycemic clamp conditions (6–8). Also, unlike GLP-1,
GIP has no effect on gastric emptying (9).
In patients with type 2 diabetes compared with healthy
subjects, the ability of GLP-1 to stimulate insulin was
noted to be 71%, while that of GIP was 46%; however, the
glucose-lowering effect of GLP-1 was relatively preserved
while that of GIP was absent (7,10–12). The underlying
pathophysiology associated with this loss of glucose-
lowering effect of GIP in humans is not known. Some
hypotheses include defective expression of GIP receptors
(13), accelerated degradation of GIP receptors (14), and
downregulation of GIP signaling (15). It is argued that
genetic components or GIP receptor defects do not play a
role in the reduced insulinotropic response to GIP because
patients with different types of diabetes, such as from
chronic pancreatitis, latent autoimmune diabetes in adults,
maturity-onset diabetes in the young, and newly diagnosed
type 1 diabetes, also have impaired insulin response to
GIP, thus suggesting that metabolic abnormalities may be
the cause (16).
The underlying pathophysiology associated with this
loss of glucose-lowering effect of GIP despite still having
some insulinotropic effect in humans is not known. The
aims of this study were 1) to ascertain if a dose of GIP
designed to elevate plasma GIP levels to ﬁvefold of that
observed postmeal might lower blood glucose in patients
with type 2 diabetes and 2) to gain insight into the
pathophysiology underlying the seeming lack of effects
of GIP on glucose homeostasis in patients with type 2
diabetes.
RESEARCH DESIGN AND METHODS
Twenty-two subjects with type 2 diabetes treated with diet alone (n  2),
metformin alone (n  13), and a metformin/sulfonylurea combination (n  7)
were recruited. These subjects had the following characteristics (means 
SD): 13 female, 9 male; 11 Caucasian, 10 African American, and 1 Hispanic;
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1342 DIABETES, VOL. 58, JUNE 2009ages 53  9 years; A1C 7.4  1.5%; BMI 37.4  7.8 kg/m
2; the average number
of years since diagnosis of diabetes 4.3  4.2 years; and no known complica-
tions from diabetes. Participants were excluded if they were on medications
that may affect glucose homeostasis or have evidence of hepatic, renal, or
hematologic abnormalities. This protocol was approved by the Intramural
Research Program of the National Institute on Aging and the institutional
review board of the MedStar Research Institute, Baltimore, Maryland.
This was a placebo-controlled crossover study. Participants who con-
sented and met the inclusion criteria based on screening clinical examination
and standard hematological and clinical chemistry measurements were stud-
ied. They stopped their hypoglycemic medication(s) for 5 days and fasted for
8 h overnight before the visit. If any of their morning fasting blood glucose
values were 240 mg/dl during any of these 5 days, they were not allowed to
participate in the study. The morning of the study, two intravenous lines were
inserted: one for blood sampling and one for delivery of saline (0.9% NaCl with
1% albumin) or human synthetic GIP (20 ng  kg
1  min
1 with 1% albumin)
(Clinalfa, La ¨ufelﬁngen, Switzerland). The GIP was synthesized in one lot, and
the GIP activity was conﬁrmed in the Chinese hamster ovary/GIP receptor
transfected cell line, where the EC50 for cAMP generation was 250  51
pmol/l. After three baseline blood draws, blood sampling took place over a 6-h
period. At time 0, each subject consumed, within 15 min, a standardized mixed
meal (440 kcal; 56% carbohydrates, 17% protein, and 27% fat) consisting of one
egg, corn ﬂakes with 2% milk, toast with margarine, and a medium banana.
The saline or GIP infusion was started with the ﬁrst bite of the meal and
maintained for 3 h. With the ﬁrst bite, 1 g (tablet form) of acetaminophen was
also given, and the appearance rate of acetaminophen in plasma was taken as
a measure of gastric emptying (17). Each subject served as his/her own
control and returned for the second visit in about 6–12 weeks.
Blood sampling. During each study, blood samples were taken at times 20,
10, and 0 min before the intervention, then every 5 min for 75 min, then every
15 min until 180 min, and then every 20 min until 360 min after the start of the
intervention for a total of 34 samples per intervention per subject. Blood
samples were collected on ice with heparinized syringes into EDTA-coated
tubes (1.5 g/ml blood) containing aprotinin (Trasylol 40 g/ml blood;
Serological Proteins, Kankakee, IL) and a dipeptidyl peptidase 4 (DPP-4)
inhibitor (10 g/ml blood, #DPP4; Linco Research, St. Charles, MO). Right
after collection, each sample was centrifuged and the plasma was pipetted
into separate aliquots and immediately frozen on dry ice and stored in 80°C
until analysis. Each aliquot contained only the amount of plasma needed for
one assay analysis; therefore, all the hormone levels were assayed from
plasma that was thawed just once. Glucose was analyzed in real time using
fresh (not frozen) samples. Study schema is shown in Fig. 1.
Plasma hormone and biochemical assays. We quantiﬁed plasma glucose
levels using a glucose analyzer (Beckman Instruments, Brea, CA). A1C was
measured with an automated DiaSTAT analyzer (Bio-Rad Laboratories, Her-
cules, CA). The plasma hormones were measured by enzyme-linked immu-
nosorbent assay (ELISA) or radioimmunoassay (RIA) methods according to
the kit manufacturers’ instructions: GIP (RIA; Phoenix Pharmaceuticals,
Belmont, CA), GLP-1 (ELISA, Linco Research, St. Charles, MO), glucagon
(with RIA; Linco Research), insulin (with ELISA; Alpco Diagnostics, Salem,
NH), and resistin (with ELISA; Alpco Diagnostics). Acetaminophen levels
were measured in the last 10 subjects. The method for measuring acetamin-
ophen levels is summarized in online appendix Section 1 (available at
http://diabetes.diabetesjournals.org/cgi/content/full/db08-0958/DC1).
Statistical analysis. The sample size of 22 in our study would provide a
power of 80% and an 0.05 to detect a 30% difference in early-phase
insulin secretion between placebo and GIP infusion of 20 ng  kg
1  min
1,
based on hyperglycemic clamp study performed in subjects with type 2
diabetes (16). Data from hyperglycemic clamp were used for sample size
calculation because no comparable study using mixed meal was found when
we designed the study.
Results are reported as means  SE. All statistical calculations were
carried out using GraphPad Prism, version 4.0 (GraphPad Software, San
Diego, CA). Values at single time points were compared by paired t test. To
account for the variation in baseline values for the hormones between studies
(placebo versus GIP), all the values were adjusted for baseline fasting value
(t  0) during the single time point analysis by subtracting every value from
its own baseline.
Area under the curve (AUC) was calculated using the trapezoidal rule and
compared using a paired t test. With fasting values (t  0) serving as baseline
levels, positive AUCs and negative AUCs corresponded to area above and
below baseline levels, respectively. The AUC for each curve, AUCALL (t 
0–360 min), was further divided into different time periods: AUC0–60(t  0–60
min), AUC60–120 (t  60–120 min), AUC120–220 (t  120–220 min), and
AUC220–360 (t  220–360 min) to better quantify the changes in hormonal
responses to placebo versus GIP. NetAUCALL is the sum of positive AUC and
negative AUC. Correlation analyses were performed between the netAUCALL
for each biochemical parameter (GIP, insulin, glucose, glucagon, GLP-1, and
acetaminophen levels) and each of the following measures: age, A1C, BMI,
and duration of type 2 diabetes. Correlation analyses were also performed
between AUCALL(t  0–180 min) for acetaminophen levels and initial rise (t 
0–20 min) in insulin and glucose levels for both placebo and GIP infusion. A
two-sided P value 0.05 was taken to indicate signiﬁcant differences.
Animals and cell lines studies: immunostaining and histologic method.
For cryosection, human islets (National Islet Cell Resource Center) and
mouse pancreata were ﬁxed in 4% paraformaldehyde, embedded in OCT
compound (Tissue-Tek; Electron Microscopy Sciences, Hatﬁeld, PA), frozen,
and stored at 80°C. Tissues were then cut with cryostat, yielding sections
7–10 m thick. Antigen retrieval (Biogenex, San Ramon, CA) was used on all
sections. Tissue was incubated with the primary insulin antibody (1:500,
guinea pig anti-insulin; Linco Research), primary glucagon antibody (1:100,
guinea pig anti-glucagon; Linco Research), or primary GIP receptor antibody
(1:200, rabbit anti-GIP receptor; MBL, Woburn, MA). Secondary antibodies
(Jackson ImmunoResearch, West Grove, PA) for immunoﬂuorescent detec-
tion of primary antibodies were animal IgGs conjuguated to Alexa Fluor 594
and 488 (1:1,000; Molecular Probes, Eugene, OR). Slides were mounted using
ﬂuorescence mounting medium (Vector Laboratories, Burlingame, CA). Im-
munoﬂuorescent pictures were captured using a Zeiss Axiovert 200M confocal
microscopy. To detect endogenous GIP receptor in TC1, the cells were ﬁxed
in 4% paraformaldehyde, permeabilized in Triton X-100 (0.25%), blocked in 3%
BSA/PBS, incubated with rabbit anti-GIP receptor antibody, and stained with
Alexa Fluor–conjugated secondary antibodies. Nuclei were labeled with
TOPRO-3 (Molecular Probes).
Intracellular cAMP determination and glucagon secretion. We assayed
intracellular cAMP as described previously (18). Brieﬂy, TC1 cells grown to
60–70% conﬂuence on six-well plates were washed with Krebs-Ringer phos-
phate buffer (KRP) and incubated with 1 ml KRP containing 0.1% BSA for 2 h
at 37°C in a humidiﬁed air incubator. Cells were then incubated in 1 ml KRP
Blood sampling 
interval:
• Glucose
• Insulin
• GIP
• GLP-1
Plasma samples
analyzed for:
75 180 360 min 0
• Glucagon
• Resistin
• Acetaminophen level
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FIG. 1. Each participant took part in two different interventions spaced 6–12 weeks apart. Starting with ingestion of a mixed meal, placebo
(normal saline) or synthetic human GIP (20 ng  kg
1  min
1) was administered intravenously for 3 h. At the same time, frequent blood samples
were taken for6ht omeasure various factors known to be involved in glucose homeostasis. With the ﬁrst bite,1go facetaminophen was also
given, and the rate of appearance of acetaminophen in plasma was taken as a measure of gastric emptying.
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presence of GIP. The reaction was stopped by washing the intact cells with
ice-cold PBS and cAMP extracted by incubating the cells in 0.1 mol/l HCl for
10 min. After centrifuging at 600g, the supernatant was directly used in the
assay. TC1 cell samples were diluted 1:1 with 0.1 mol/l HCl, and we assayed
all samples using a cyclic AMP (direct) EIA Kit (Assay Designs, Ann Arbor,
MI). To check for speciﬁcity of GIP action, we incubated cells, as outlined
above, and measured glucagon secretion into the medium in the presence of
GIP with or without a GIP receptor antagonist GIP (3–42) (New England
Peptide, Gardner, MA).
RESULTS
Human study. The average fasting values (t  0) for all
plasma glucose and hormones were not statistically differ-
ent between placebo and GIP intervention: GIPplacebo 
43.3  6.5 pmol/l, GIPGIP  47.9  10.0 pmol/l, P  0.408;
insulinplacebo  12.7  1.5 U/ml, insulinGIP  11.5  1.1
U/ml, P  0.220; glucoseplacebo  159.3  11.0 mg/dl,
glucoseGIP 155.0 10.0 mg/dl, P0.431; glucagonplacebo 
99.1  8.4 	g/ml, glucagonGIP  107.7  9.7 	g/ml, P  0.054;
and GLP-1placebo  5.1  0.9 pmol/l, GLP-1GIP  5.4  1.0
pmol/l, P  0.205. Mixed meal alone induced an increase in
fasting GIP levels in placebo from 43  6t o9 1 10
pmol/l (average from 60 to 180 min). When GIP was
infused from 0 to 180 min with a meal, mean GIP levels
went from 48  10 pmol/l at baseline to 495  44 pmol/l
(average from 60 to 180 min) (Fig. 2A). Upon termination
of infusion, GIP levels rapidly decreased and approached
fasting levels by the end of the study. As expected, the
difference in plasma GIP levels between placebo and GIP
infusion was statistically signiﬁcant (P  0.001) at all time
periods, as calculated by both single time point compari-
sons and AUC analyses (Fig. 2A and Fig. 3A-1–A-2).
GIP infusion was associated with an early transient
increase in plasma insulin and a late postprandial
elevation of plasma glucose. Compared with placebo,
GIP induced a statistically signiﬁcant increase in plasma
insulin during the early postprandial period (t  0–60
min), as noted in Fig. 2B and as a larger positive insulin
AUC0–60 (P  0.01) (Fig. 3B-2). However, the increase in
insulin level was accompanied by only an early transient
decrease in plasma glucose (Fig. 2C), as demonstrated by
a greater negative glucose AUC0–60(P  0.05) (Fig. 3C-2).
Intriguingly, GIP also induced a statistically signiﬁcant
elevation in plasma glucose from 120 to 360 min (Fig. 2C),
as noted by a signiﬁcantly larger positive AUC120–220 (P 
0.001), and less suppression of plasma glucose, as demon-
strated by a smaller negative AUC220–360 (P  0.05) (Fig.
3C-1–C-2). To further understand why an increase in
plasma insulin from 0 to 60 min was not associated with a
decrease in plasma glucose, and to elucidate the underly-
ing cause of elevation in plasma glucose from 120 to 360
min, we measured plasma glucagon, GLP-1, resistin, and
acetaminophen levels (as a measure of gastric emptying).
GIP infusion was associated with a signiﬁcant in-
crease in early postprandial plasma glucagon and a
signiﬁcant decrease in late postprandial plasma
GLP-1 levels. With GIP administration, a statistically
signiﬁcant augmentation in glucagon secretion was noted
between 0 and 60 min (Fig. 2D), as shown by larger
positive AUC0–60 (P  0.01) (Fig. 3D-2). A signiﬁcant
decrease in GLP-1 secretion was noted (Fig. 2E), as
measured by both positive and negative AUCALL, and is
most prominent in the last postprandial period (120–360
min) (P  0.05) (Fig. 3E-1–E-2).
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FIG. 2. When compared with placebo, exogenous GIP infusion not only
did not lower postprandial glucose but further worsened hyperglyce-
mia during late postprandial period (120–360 min) in patients with
type 2 diabetes. GIP infusion at a pharmacologic dose (20 ng  kg
1 
min
1) during a mixed meal is associated with a ﬁvefold increase in
plasma GIP levels (A), an early transient increase in plasma insulin
(0–60 min) (B), a late postprandial elevation of plasma glucose
(120–360 min) (C), a signiﬁcant early postprandial increase in plasma
glucagon (0–60 min) (D), and a signiﬁcant decrease in late postpran-
dial plasma GLP-1 levels (120–360 min) (E). GIP or placebo infusion
was started a time 0 and continued for 180 min. A mixed meal was given
at time 0. Data are presented as means  SE. *Signiﬁcant (P < 0.05)
differences between GIP versus placebo at individual time points
relative to baseline at t  0. Blue circle, placebo; orange circle, GIP.
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emptying. GIP administration had no effect on resistin
levels during3ho fG I Po rplacebo infusion (data not
shown). It also did not affect gastric emptying, as plasma
acetaminophen levels were comparable in both groups
with no signiﬁcant difference between the AUCALL (t 
0–180 min) for acetaminophen levels from GIP and pla-
cebo infusion (Fig. 4). There was also no correlation
between the AUCALL (t  0–180 min) for acetaminophen
levels and the initial rise in insulin or glucose during either
placebo or GIP infusion (data not shown). The character-
istics of the 10 subjects in which acetaminophen levels
were measured did not statistically differ from those of the
entire study cohort (data not shown).
Correlation analyses were performed to determine
whether the observed effects were inﬂuenced by factors
such as glycemic control, duration of diabetes, BMI, and
age. There was no correlation between the netAUCALL for
each of the biochemical parameters (GIP, insulin, glucose,
glucagon, GLP-1, and acetaminophen levels) and each of
the patients’ measures (age, A1C, BMI, and duration of
type 2 diabetes) (data not shown).
Animal and cell line studies. To understand how GIP
might induce glucagon secretion, we used in vitro models.
First, we looked for the presence of GIP receptors in
mouse and human islets and found them to be present in
both - and 
-cells (Fig. 5A and B). We also found GIPR in
TC1 cells, an -cell line (Fig. 5C). Stimulating these cells
with GIP led to increased intracellular cAMP and glucagon
secretion in a concentration-dependent manner (Fig. 5D
and E). Furthermore, in TC1 cells, GIP-mediated gluca-
gon secretion was diminished in the presence of a GIP
receptor antagonist (Fig. 5F).
DISCUSSION
In this study, we sought to determine the role of a
supraphysiologic dose of exogenous GIP on postprandial
glucose homeostasis in patients with type 2 diabetes in
order to understand the pathophysiology underlying the
lack of glucose-lowering effect of GIP in type 2 diabetes.
We administered a mixed meal to each subject to induce
an elevation in blood glucose and started GIP infusion at
the ﬁrst bite of the meal. We showed that in patients with
type 2 diabetes, a mixed meal of 440 kcal induced a
gradual rise in GIP from fasting levels of 43 pmol/l to a
peak of 91 pmol/l at 60 min followed by a slow decline
back to fasting levels. GIP infusion at a dose of 20 ng 
kg
1  min
1 increased plasma GIP concentration to 500
pmol/l for the duration of the infusion (a ﬁvefold increase
relative to placebo, which is comparable with another
study where GIP was given at the same dose and by the
same route) (16).
GIP infusion induced a moderate, but statistically signif-
icant, early insulin response from 0 to 60 min, with no
accompanying decrease in plasma glucose during the
same time period. The presence of early postprandial
insulin response to GIP is supported by the ﬁndings of
Vilsboll et al. (12), where they showed that in response to
GIP infusion during a hyperglycemic clamp, patients with
type 2 diabetes still have early insulin response (0–20
min), although the response was delayed and reduced.
However a late-phase insulin response was lacking (20–
120 min).
We also found that GIP induced a statistically signiﬁcant
increase in glucose levels during the late postprandial
period (120–360 min) when the insulin levels were com-
parable between the placebo and GIP infusion subjects.
Therefore, either GIP itself is glucogenic in patients with
type 2 diabetes or GIP modulates some other factors or
hormones that are glucogenic, or increase insulin resis-
tance, or both. To our knowledge, this observation has not
been previously reported.
GIP has been shown in hyperglycemic clamp studies to
have no effect on glucagon levels in type 2 diabetes (7,16).
In other studies, patients with type 2 diabetes are reported
to show a paradoxical rise of glucagon levels after inges-
tion of carbohydrate or protein (19,20). The present glu-
cagon data following ingestion of a mixed meal with
placebo infusion are in agreement with these later obser-
vations. With a mixed meal, and therefore a more physio-
logical paradigm, we show that, relative to placebo, GIP
infusion caused a statistically signiﬁcant rise in early
postprandial (0–60 min) glucagon levels. This increase in
glucagon secretion would explain the lack of glucose-
lowering effect of GIP in the early phase even though GIP
is insulinotropic and can induce a statistically signiﬁcant
increase in insulin levels.
Using an in vitro cellular system, we were able to show
that the elevation in glucagon secretion with GIP infusion
can be explained by the presence of GIP receptors on
human islets and by the ability of GIP to induce glucagon
secretion in vitro. To our knowledge, this is the ﬁrst time
GIP receptors have been shown to be present on human
-cells. Other investigators have detected GIP receptors
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including both - and 
-cells (21). GIP receptor mRNA
expression has also been found in rat pancreatic -cells,
and GIP-stimulated increase in cAMP levels was demon-
strated in puriﬁed rat -cells (22). Furthermore, GIP has
also been shown to stimulate glucagon release from
perfused rat pancreas (23) and human pancreata (24) and
to increase plasma glucagon in rats (25).
Obviously, plasma glucagon levels cannot explain why
glucose was elevated with GIP infusion during the late
postprandial phase (120–360 min) because glucagon levels
were already at the level of placebo by this time. We found
that the elevation in glucose during late postprandial
phase with GIP infusion (ranging from 5 to 14 mg/dl
without adjusting for differences in fasting glucose levels
between placebo and GIP infusion [with baseline adjust-
ment, the differences in glucose elevation would be 10–19
mg/dl]) may be explained by the suppressive effect of
exogenous GIP infusion on GLP-1. The observed reduction
in GLP-1 level is small but signiﬁcant using AUC analysis
and may explain the similarly modest but signiﬁcant
increase in blood glucose. GLP-1, in addition to its many
other effects, has also been shown to activate hepato-
portal glucose sensor and increase hepatic glucose uptake
in dogs (26). The lower GLP-1 level with GIP infusion
would, in theory and in keeping with published research,
lower hepatic glucose uptake and therefore decrease the
clearance rate of glucose out of plasma by the liver during
postprandial period. To our knowledge, only one other
study examined the effect of exogenous GIP infusion on
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subjects and subjects with type 2 diabetes. No changes in
GLP-1 levels during infusion was found (7). GIP doses in
that study were 4 and 12 ng  kg
1  min
1 and were given
only during hyperglycemic clamp. Our study used 20 ng 
kg
1  min
1 and physiologic simulation with mixed meals
during clamp. Other studies using in situ models of iso-
lated, vascularly perfused rat ileum preparation and iso-
lated, perfused segments of porcine ileum and in vitro
studies using GLP-1 release assay based on primary canine
intestinal L-cells and GLUTag cells line, demonstrated that
GIP stimulated GLP-1 secretion (27–30). Taken together,
the regulation of GLP-1 secretion is complex where in
vitro and in situ models might not be representative of
actual human physiology. These data are, however, in line
with what happens when DPP-4 inhibitors are used. In that
case, the elevated plasma active GIP and GLP-1 levels
cause a decrease in incretin secretion (31). How exoge-
nous GIP administration suppresses GLP-1 secretion in
humans needs further research.
Several studies have shown that GIP does not affect
gastric emptying, and our assessment of gastric emptying
using plasma acetaminophen levels is in agreement with
them (9,32). Even though acetaminophen level is not an
optimal marker to measure gastric emptying, it has been
shown to correlate well to the gold standard of gastric
emptying measurement using scintigraphy (17). Therefore,
unlike GLP-1, which partly modulates postprandial glu-
cose homeostasis through delaying gastric emptying, GIP
does not appear to share this property.
In a recent study examining how endogenous incretin
receptors control glucose homeostasis using Glp1r
/ and
Gipr
/ mice, plasma resistin levels were found to be
signiﬁcantly increased after GIP analog administration in
wild-type and Glp1r
/ mice but not in Gipr
/ mice (33).
We measured resistin levels in our study to see whether
GIP affects resistin levels in humans. Our results showed
comparable resistin levels between placebo and GIP infu-
sion subjects. This difference between mice and humans
can partly be explained by the ﬁndings that human fat
cells, unlike those of mice, do not produce resistin (34,35).
In humans, resistin is expressed and secreted by bone
marrow and peripheral mononuclear cells (36). This also
underscores the necessity for human studies to see if
rodent ﬁndings have physiological signiﬁcance in humans.
This study has certain limitations. First, a relatively
large dose of GIP was infused with only one meal, and a
dose-response GIP-glucagon would have been helpful.
Second, the group of patients studied was heterogeneous
in their clinical characteristics; therefore, there might be
unmeasured variability in responses to GIP that are tied to
each subject’s unique characteristics.
In conclusion, GIP, given at a pharmacological dose
with a meal, still has an early, short-lived insulinotropic
effect in type 2 diabetes. However, with a concomitant
increase in glucagon levels, the glucose-lowering effect
was lost. Exogenous GIP infusion further worsened hyper-
glycemia in the late postprandial stage, most likely
through its suppressive effect on GLP-1 secretion. If it is
conﬁrmed that the use of GIP and GIP receptor agonists
results in changes in glucose homeostasis, as shown here,
then it is unlikely that they will be useful as glucose-
lowering agents in type 2 diabetes.
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